Objectives: The present study assessed whether human telomerase reverse transcriptase (TERT) promoter mutations mediate the increased mortality risk observed in patients with ovarian clear cell carcinoma (CCC) and characterized the pathologic features of TERT promoter mutation-associated ovarian CCC.
Ovarian cancer is the eighth leading cause of cancer mortality among women internationally. 1 There are more than 10 histologic subtypes of ovarian cancer, which are classified into two groups (type I and type II tumors) based on their source cell type and molecular mode of pathogenesis. 2 Type I tumors are usually large, unilateral, cystic tumors that develop from preexisting benign extra ovarian lesions that implant on the ovary and subsequently undergo a malignant transformation. They are character ized by an excellent prognosis while still confined to the ovary. Type II tumors are usually small, highly aggressive, and frequently disseminating tumors that develop from intraepithelial carcinomas in the fallopian tube.
Clear cell carcinoma (CCC) is a type I tumor that predominantly arises from endometriosis. Patients with early stage ovarian CCC usually exhibit a better prognosis than those with other type I histologic subtypes; however, some patients with a form of CCC that is associated with an increased telomere length instead experience a poorer prognosis equivalent to that exhibited by patients with type II tumors (mostly composed of serous carcinoma). 3, 4 Thus, telomerase activity seems to be a key molecule for CCC prognosis. A functional role of telomerase is also supported by the recent findings that adenine-thymine-rich interactive domain 1A (ARID1A), a tumor suppressor that most often mutates in CCC, negatively regulates expression of telomerase, and a loss of ARID1A protein expression caused by inactivating mutations reactivates telomerase activity and confers a survival advantage to tumor cells.
Telomerase activity is most commonly determined by the transcriptionlevel expression of human telomerase reverse transcriptase (TERT). Many human cancers are pos tulated to result from promoter mutations that enhance transcription, and indeed, hotspot mutations at positions -124 and -146 base pairs (bp) from the ATG translation start site of the TERT promoter have been previously shown to contribute to the pathogenesis of melanoma, hepatoma, and glioma, as well as that of breast, thyroid, prostate, and ovarian cancer. 3, 611 While CCC has been reported to be the ovarian cancer subtype most frequently (15.9%) associated with TERT promoter mutations, these do not appear to re duce the patient diseasefree survival rate, 12 and indeed, a very recent study found TERT promoter mutation to be correlated with an improved prognosis for early stage patients. 3 Thus, while TERT promoter mutations appear to be a unique feature of ovarian CCC, the known hotspot mutations are not sufficient to cause the observed decreased patient survival rate. In the present study, we investigated the effect of alternative TERT promoter mutations on the decreased survival rate of patients with ovarian CCC and examined the pathologic features of CCC associated with TERT promoter mutations.
Materials and Methods

Patient Characteristics, Histologic Coexistence of Lesions and CCC, and Immunohistochemical Analysis for BAF250a
The present study was approved by the institu tional review board of the Chiba University Graduate School of Medicine (1903) . Surgically treated ovar ian CCC cases without residual tumors (n = 93) were retrieved from Chiba University and affiliated hospi tals. These cases were examined during an earlier study by our research group, which investigated the associa tion between BAF250a expression (as encoded by the ARID1A gene) and CCC with adenofibroma and/or endometriosis. 13 Clinical data obtained from patient records showed the median patient age to be 56 years (range, 3284 years). According to the International Federation of Gynecology and Obstetrics (FIGO) 1988 surgical staging system, 27, one, 58, four, one, and two of the patients were found to exhibit stage IA, IB, IC, IIC, IIIA, and IIIC cancer, respectively.
Prior to use, all H&Estained ovarian tumor slides (224 per tumor; median, 8) were independently reviewed by two gynecologic pathologists (T.K. and M.I.) to confirm their diagnosis according to the World Health Organization criteria. 14 Previous studies have revealed that two types of be nign lesions, endometriosis and adenofibroma, may occur concomitantly with ovarian CCC. Patients predominantly exhibit only one type of concomitant benign lesion, but a small number of patients exhibit both. Thus, the slides were analyzed for the presence of coexistent benign ade nofibroma and/or endometriosis lesions. The results of this analysis showed that 18, 45, 18, and 12 of the patients with ovarian CCC also exhibited adenofibroma alone, endometriosis alone, both conditions, and neither condi tion, respectively. The various adenofibroma lesions were defined as being either clear cell and/or unclassifiable ade nofibroma with a flat epithelium.
In our previous study, 13 we detected a loss of BAF250a expression in five (28%) of 18, 30 (67%) of 45, eight (44%) of 18, and seven (58%) of 12 carcinoma cases associated with adenofibroma alone, endometriosis alone, both conditions, and neither adenofibroma nor en dometriosis, respectively. Representative H&E staining and immunohistochemical detection of BAF250a expres sion in adenofibromaassociated CCC samples are shown in ❚Image 1❚.
DNA Extraction and Mutation Analysis
Sections (4 µm thick) were cut from the same for malinfixed, paraffinembedded tissue blocks used for BAF250a immunohistochemistry. The sections were deparaffinized with xylene (Wako, Osako, Japan), and tumor components were manually dissected (27gauge nee dles) under a microscope to exclude contamination with normal tissue. Genomic DNA was extracted from the dis sected tumorous tissue using the QIAmp DNA Micro kit (Qiagen, Tokyo, Japan) according to the manufacturer's instructions. The chromosome 5 (hg19) TERT promoter region containing the hotspot mutations at positions 1 295 228 and 1 295 250 (located at −124 and −146 bp from the ATG translation start site, respectively) were amplified via a polymerase chain reaction (PCR), using M13 universal sequencing (5′GTAAAACGACGGCCAGT3′), forward (5′M13CAGCGCTGCCTGAAACTC3′) and reverse (5′GTCCTGCCCCTTCACCTT3′) primers, and cycling conditions comprising 95°C for 300 seconds, followed by 35 cycles of 98°C for 10 seconds, 58°C for 15 seconds, 68°C for 8 seconds, and a final cycle of 72°C for 600 seconds ❚Figure 1❚. The generated PCR products were purified using the QIAquick PCR Purification Kit (Qiagen) accord ing to the manufacturer's instructions. Purified amplifi cation products were submitted for sequencing using the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) and purified using the BigDye X Terminator Purification Kit (Applied Biosystems). Sequences were determined using the ABI PRISM 310 genetic analyzer (Applied Biosystems) and Sequencing Analysis Software version 5.2 (Applied Biosystems).
Sequencing fidelity was confirmed between posi tions -110 and -160 of the TERT promoter via reverse sequencing. Genomic DNA isolated from normal myo metrial/blood specimens from each patient was also sequenced to exclude germline mutations. In instances where the height of a minor peak was found to be greater than 10% of that of the corresponding major peak, het erogeneity was determined via an analysis of the appro priate electropherogram.
Statistical Analysis
Patient 5year progressionfree survival (PFS) and overall survival (OS) rates were calculated using the KaplanMeier method. Differences in patient sur vival with respect to their TERT promoter mutation status were assessed using a logrank test, where a P value less than .05 was considered to indicate statisti cal significance. A CochranArmitage test was used to assess mutation rate trends across the analyzed surgical stages.
A χ 2 test was used to analyze the association between TERT promoter mutations and the concomitant presence of adenofibroma/endometriosis with CCC. All tests were twotailed, where a P value less than .05 was considered ❚Image 1❚ Representative ovarian clear cell carcinoma (CCC) and adenofibroma samples after H&E staining (A, C) and immunohistochemical analysis of BAF250a expression (B, D) (×100). B, BAF250a expression is retained in both the adenofibroma and ovarian CCC samples. D, BAF250a expression is retained in the adenofibroma but lost in the ovarian CCC samples.
to indicate statistical significance. Data were analyzed using JMP software version 11 (SAS Institute, Cary, NC).
Results
TERT Promoter Mutation Genotypes
TERT promoter mutations were identified in 24 (26%) of the 93 analyzed ovarian CCC cases, including a single case that harbored two TERT promoter muta tions. Of the 25 identified mutations, 11 (seven C124C/T mutations, one C124T mutation, two C146T mutations, and one C146C/T mutation) were hotspot mutations, while 14 (one C127C/T mutation, three G129G/T muta tions, one G129G/A mutation, two G135G/A muta tions, one G135G/T mutation, one G141G/A mutation, one C144T mutation, two C154C/A mutations, one C154C/G mutation, and one C154T mutation) were uncommon mutations ❚Figure 2❚ (Supplemental Table 1 ; all supplemental materials can be found at American Journal of Clinical Pathology online). Among the iden tified uncommon mutation sites, -129, -135, and -154 were novel and exhibited two or three types of nucleotide substitution (ie, both transition and transversion muta tions) each. This is a distinctive feature because known TERT mutations at other sites, including the hotspot mutations, are transversion only.
Patient Characteristics and TERT Promoter Mutations
Clinical characteristics were compared between both patients with and without TERT mutations and those with uncommon vs hotspot mutations. The analyzed clin ical factors included history of disease (hypertension, dia betes mellitus, and cancer other than ovarian), medicine use (oral contraceptives and/or estrogen replacement), menstrual status (menopause, oligomenorrhea/amenor rhea), and chemotherapy administration for the ovarian cancer. No statistically significant differences in patient characteristics were observed between any of the groups.
All hotspot mutations were identified in patients with (FIGO 1988) stage I cancer, whereas uncommon mutations were identified in 11 of the 86 identified patients with stage I cancer, one of the four identified patients with stage II cancer, and two of the three identified patients with stage III cancer ❚Table 1❚. 15 The association between the surgical stage and proportion of mutationpositive CCC cases was analyzed using a CochranArmitage trend test. A linear trend showing the more advanced surgical stage cases to be associated with a higher proportion of uncommon muta tions was identified (Supplemental Table 2 ). In contrast, no association was detected for the hotspot mutations. These results suggest that uncommon mutations develop during disease progression.
Prognostic Impact of TERT Promoter Mutations
An analysis of the association between TERT pro moter mutations and patient survival showed that the PFS rate was the same for patients with and without hotspot mutations ❚Figure 3❚. In contrast, patients with uncommon site mutations (at -127, -129, -135, -141, -144, or -154 bp) exhibited a reduced PFS rate compared with patients in whom they were absent (P < .01, log rank test), such that the 10year PFS rates were 46% and 82% for patients with and without uncommon site muta tions, respectively (Figure 3) . The presence of hotspot or uncommon site mutations was not found to significantly affect the patient OS rate (Figure 3) .
Association of TERT Promoter Mutations With the Coexistent Lesions
TERT promoter mutations were identified in nine (50%) of 18 CCC cases with adenofibroma alone, 12 (27%) of 45 cases with endometriosis alone, nine (50%) of 18 cases with both conditions, and one (8%) of 12 cases with neither condition. The conducted logistic regression analysis of the 18 patients found to exhibit both endometriosis and adenofibroma revealed that, while the presence of the identified TERT mutations was positively correlated with the coexistent presence of adenofibroma (P = .03, χ 2 test), it was unrelated to the coexistence of endometriosis (P = .80, χ 2 test)
A subsequent subset analysis of these positive cor relations showed the association between the coexistence of adenofibroma and TERT promoter mutations to be statistically significant for the hotspot mutations (P = .02, χ 2 test) but not for the uncommon mutations (P = .38, χ 2 test) ( Table 2) .
Relationship of the TERT Promoter Mutations With BAF250a Expression Loss
Of the 50 ovarian CCC cases found to exhibit a loss of BAF250a expression, 15 (30%) were identified to harbor TERT promoter mutations. Conversely, of the 43 ovarian CCC cases shown to exhibit retained BAF250a expres sion, nine (21%) were found to harbor TERT promoter mutations. Thus, the observed TERT promoter mutations and BAF250a expression loss were not mutually exclusive (P = .43, χ 2 test) ( Table 2) . 
Analysis of Mutation Topologic Heterogeneity
To examine whether the identified TERT muta tions occur exclusively in cancer cell populations, we next examined adenofibroma lesions that were coexist ent with TERT mutationpositive CCC. Sufficient ade nofibroma samples to conduct a paired analysis were microdissected from five patients, three and two of whom exhibited uncommon and hotspot mutations, respectively. The coexistent adenofibroma samples were all shown to be negative for TERT mutations, while in contrast, their paired CCC samples were all TERT mutation positive.
As discussed, the increased rate of TERT mutations across the analyzed surgical stages suggests that uncom mon mutations likely occur during tumor progression. To verify this hypothesis, we next analyzed the heterogeneity of tumor cell populations that were isolated from addi tional CCC tissue specimens microdissected from the tis sue slides of both TERT mutationpositive (n = 5) and mutationnegative (n = 5) CCC cases (ie, independent of the initial sampling sites). The presence/absence and type of identified TERT mutations were shown to be identi cal at the initial and additional sites for all sample pairs; however, variation was observed in the mutant/normal alleleheight electropherogram ratios generated at the ini tial and additional TERT mutationpositive sample sites.
Discussion
In the present study, we investigated TERT promoter mutations in ovarian CCC and resultantly identified uncommon site mutations that included three novel muta tion sites, as well as two wellknown hotspot mutations. The uncommon site mutations were shown to be associated with poor prognosis but not with the presence of adeno fibroma or with BAF250a expression loss. Conversely, the hotspot mutations were significantly associated with the presence of adenofibroma but not with patient prognosis.
Furthermore, the uncommon mutations were shown to be cancer cell specific, since they were not detected in adenofibroma lesions that were coexistent with the ana lyzed CCC tissue samples. They were also found to occur more frequently in CCC cases of increasingly advanced surgical stages, and various analyzed singletumor CCC cell populations were shown to be topologically hetero geneous for the uncommon mutations. Taken together with the observed effect of the uncommon mutations on patient prognosis, these data suggest that the uncommon mutations likely occur during CCC progression, perhaps driving tumor growth via TERT promoter activation.
TERT promoter hotspot mutations are one of the most frequent mutation types to affect the promoter region of tumorrelated genes, although notably, their effect on patient prognosis varies in different cell types. 16 A significant asso ciation has been identified between the presence of TERT promoter mutations and poor prognosis in patients with a range of tumor types, including glioblastoma, 17 urothelial carcinoma, 18 bladder carcinoma, 19 and adrenocortical car cinoma. 20 In contrast, while TERT promoter mutations are often harbored by patients with lung cancer, 21 hepatocellular carcinoma, 22 and/or cutaneous squamous cell carcinoma, 23 no association has been previously observed between their presence and the prognosis of patients with these diseases. Thus, the prognostic effect of TERT hotspot mutations appears to be cell type specific. As discussed, the currently available data describing the association of TERT hotspot mutations with patient prognosis for ovarian CCC are inconsistent. 3, 12 Recently, novel (nonhotspot) TERT promoter mutations were iden tified in bladder tumor cells and their derived cell lines (comprising -45 C > A, -57 T > G, -138/-139 GG > AA, -72 G > C, -77 G > A, and -141 C > A), 9 as well as in mel anoma cells (eg, -57 T > G and -138/-139 GG > AA).
9,23
The present study identified uncommon site mutations in patients with ovarian CCC and demonstrated that these, rather than the previously reported hotspot muta tions, exerted a significant impact on patient prognosis. Further studies are required to clarify whether the identi fied uncommon site mutations are specific to the analyzed Japanese population, which notably exhibits a higher rate of ovarian CCC than is observed in white populations.
Further studies are also required to elucidate the molecular mechanisms that underlie the effect of the identified uncommon mutations on patient prognosis. The hotspot mutations at positions -124 and -126 have been shown to generate a new consensus binding site (TTCCGG) for Etwentysix (ETS) transcription factors just proximal to the transcription start site, likely induc ing a modest increase in transcription. 6, 24, 25 Recently, it has been suggested that the TERT promoter hotspot mutations may cause TERT expression silencing to fail during the differentiation of embryonic stem to somatic cells. 26 This silencing is known to be critical to maintain growth control checkpoints prior to replicative senes cence in somatic cells. More recently, the GAbinding protein transcription factor, a member of the ETS family, has been shown to bind to the de novo ETS motif and thereby activate transcription in cell lines such as GBM1, U251, and HepG2. 27 Thus, the hotspot mutationinduced activation of the TERT promoter may be context depen dent in different cancer cell types and likely involves the binding of more than just a single ETS factor. 28 In contrast, none of the uncommon mutations iden tified in the present study give rise to de novo ETS bind ing sites. Instead, they are concentrated in a short, 28bp region. All substitutions (except the hotspot mutations) identified within this region worsened patient prognosis, regardless of the types of bases that were substituted. Three of the six identified uncommon mutations com prised both transversion and transition mutations, while all types of base substitutions were found to occur at position -154, suggesting that the uncommon mutations likely function in a locusdependent but sequencein dependent manner. In contrast, the hotspot mutations at positions -124 and -146 both comprise only CtoT transversion mutations, suggestive of contextdependent promoter activation. Taken together, these findings led us to hypothesize that some transcription factor(s) may normally bind to this region and inhibit its transcription; thus, introduced base substitutions may block the binding of these factor(s) and thereby disrupt their function, in turn resulting in TERT transcriptional activation. A con ducted in silico analysis of the wildtype sequence at this region predicts putative binding sites for several transcrip tion factors that may inhibit TERT transcription. These include myeloid zinc finger 1 (MZF1), which is a tran scription factor that has been previously identified as a TERT transcriptional repressor 29 and predicted to have several potential binding sites in this region that require experimental confirmation (Figure 1 and Supplemental Figure 1 ). 29 Similarly, transcription factor AP2 alpha (TFAP2) is a transcription factor that functions as both a transcriptional activator and repressor dependent on the target gene being transcribed, which is predicted to bind to the same TERT promoter region. There are many other predicted transcription factor binding sites of within this GCrich region of the TERT promoter; however, further study is required to determine the molecular mechanism by which uncommon mutations affect the prognosis of patients with ovarian CCC.
Two types of pathologies, endometriosis and adeno fibroma, are proposed to be precursor lesions for ovarian CCC. Endometriosis is often observed to affect ovarian CCC specimens and is well established to be associated with a number of oncogenic mutations. For example, ARID1A mutations, which are estimated to affect 39% to 100% of carcinomaadjacent and atypical endometri osis cases, are considered an early event in the oncogenic transformation process. 3033 Similarly, adenofibroma, which is a suspected onco genic lesion characterized by the proliferation of the benign glandular epithelium that is surrounded by ovar ian stromalike cells, is observed in 10% to 20% of ovar ian CCC cases. 3436 Furthermore, adenofibroma that is observed in ovarian CCC specimens is often associated with a transitioning malignant epithelial and/or a mixed benign/malignant glandular epithelial cell population. 37, 38 We recently reported that adenofibroma is more prevalent than previously estimated and often coexistent with endo metriosis and/or ovarian CCC; nevertheless, the molec ular features of adenofibromaassociated ovarian CCC have not yet been well characterized. Yamamoto et al pre viously established that, in terms of cytogenetic changes, the rate of heterozygosity loss at chromosomes 3p, 5q, and 11q and the frequency of PIK3CA mutations are both reduced in adenofibromaassociated compared with endometriosisassociated ovarian CCC. 31, 36 Similarly, we recently reported BAF250a production to be lower in ade nofibromaassociated than in endometriosisassociated ovarian CCC specimens, 13 and likewise, the present study revealed that the presence of the identified hotspot TERT promoter mutations was associated with adenofibroma but not with endometriosis. Taken together, these findings suggest that the molecular features of adenofibromaas sociated ovarian CCC are different from those charac teristic of ovarian CCC coexistent with endometriosis. Interestingly, the results of the present study are in direct contrast to those reported by Wu et al 12 in suggesting that TERT promoter mutations are not mutually exclusive with BAF250a expression. This discrepancy may reflect the different immunohistochemical detection methods, data evaluation criteria, and ethnicities of the study par ticipants used by the two studies and/or the inclusion of novel mutations in the present study. Notably, the pres ent study was a multicenter retrospective study, and thus the size of available tumor specimens was variable and, in some cases, limited.
Certainly, the small sample number was a limitation of the present study. The number of patients was as low as one to four for each uncommon mutation site, so the conducted statistical analysis had to be performed by grouping all mutations (except the two hotspot muta tions) together. Thus, further studies are needed to ana lyze a greater number of CCC cases before the impact of the identified uncommon mutations can be accurately assessed.
In conclusion, TERT promoter hotspot mutations are likely a molecular feature of adenofibromaassociated CCC. Conversely, the identified uncommonsite TERT promoter mutations appear to be associated with a poor patient prognosis; however, further study is required to
